Instil Bio Resumes ITIL-306 Study In Lung, Ovarian, Renal Cancers

Instil Bio Inc TIL has resumed its Phase 1 clinical trial of ITIL-306 for non-small cell lung cancer (NSCLC), ovarian cancer, and renal cell carcinoma (RCC).
With the resumption of the ITIL-306 Phase 1 study, the company plans to release initial safety, translational, and efficacy data from dose escalation cohorts at a medical conference in 2023.
The trial was resumed after implementing additional quality safeguards designed to further protect the manufacturing process from potential contaminants.
Related: Instil Bio Discontinues ITIL-168 Cancer Trials, Layoffs 60% Of Its Employees.
Following its recent reprioritization of clinical programs and corporate restructuring, Instil expects its cash runway to extend into 2025, excluding the potential financing or other monetization of its Tarzana manufacturing site.
Instil intends to provide further updates on its pre-clinical pipeline in 2023, including the potential to nominate additional CoStAR candidates and novel TIL technologies for clinical development.
Price Action: TIL shares are up 2.75% at $0.6511 on the last check Monday.